12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Nektar, Royalty Pharma sales and marketing update

Nektar agreed to sell its royalty rights to anemia drug Mircera methoxy polyethylene glycol-epoetin beta and autoimmune drug Cimzia certolizumab pegol to Royalty Pharma for $124 million. Nektar said it will use the money to repay part of its $215 million in convertible debt. The company received $8.3 million in total royalties from sales of the two drugs last...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >